Pasithea Therapeutics Corp./$KTTA
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Pasithea Therapeutics Corp.
Pasithea Therapeutics Corp is a biotechnology company. It is focused on the discovery, research, and development of treatments for central nervous system (CNS) disorders and other diseases, including RASopathies and certain cancers. It leveraging in the fields of neuroscience, translational medicine, and drug development. The disorders covered includes Neurofibromatosis Type 1, Amyotrophic Lateral Sclerosis (ALS), Multiple Sclerosis (MS), and Schizophrenia. Companies pipelines includes PAS-004 (Macrocyclic Small Module[MEK1/2]), PAS-003 (Monoclonal antibody),PAS-001 (Small Module). The Company has reportable segment, which is the business of research and development of treatments for central nervous system (CNS) disorders and other diseases, including RASopathies and certain cancers.
Ticker
$KTTA
Sector
Primary listing
Employees
5
Headquarters
Website
KTTA Metrics
BasicAdvanced
$17M
-
-$2.91
0.25
-
Price and volume
Market cap
$17M
Beta
0.25
52-week high
$3.79
52-week low
$0.28
Average daily volume
469K
Financial strength
Current ratio
11.351
Quick ratio
11.09
Profitability
EBITDA (TTM)
-16.031
Management effectiveness
Return on assets (TTM)
-27.35%
Return on equity (TTM)
-58.36%
Valuation
Price to book
0.29
Price to tangible book (TTM)
0.31
Price to free cash flow (TTM)
-0.324
Free cash flow yield (TTM)
-309.07%
Free cash flow per share (TTM)
-2.163
Growth
Earnings per share change (TTM)
-77.10%
3-year earnings per share growth (CAGR)
-35.92%
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Pasithea Therapeutics Corp. stock?
Pasithea Therapeutics Corp. (KTTA) has a market cap of $17M as of April 13, 2026.
What is the P/E ratio for Pasithea Therapeutics Corp. stock?
The price to earnings (P/E) ratio for Pasithea Therapeutics Corp. (KTTA) stock is 0 as of April 13, 2026.
Does Pasithea Therapeutics Corp. stock pay dividends?
No, Pasithea Therapeutics Corp. (KTTA) stock does not pay dividends to its shareholders as of April 13, 2026.
When is the next Pasithea Therapeutics Corp. dividend payment date?
Pasithea Therapeutics Corp. (KTTA) stock does not pay dividends to its shareholders.
What is the beta indicator for Pasithea Therapeutics Corp.?
Pasithea Therapeutics Corp. (KTTA) has a beta rating of 0.25. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.